



I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.

BY:

*Carol Taylor*

DATE: *November 6, 2000*

*J. Davis*  
PATENT  
*0100*

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent Application of : Group Art Unit: 1633  
Darwin J. Prockop *et al.* :  
Appln. No.: 09/028,395 : Examiner: Janet M. Kerr  
Filed: February 24, 1998 :  
For: ISOLATED STROMAL CELLS FOR USE : Attorney Docket  
IN THE TREATMENT OF DISEASES OF : No. 9598-32US  
THE CENTRAL NERVOUS SYSTEM : (209598.0032)  
: AUHS-318  
:

## RESPONSE TO OFFICE ACTION

This Response responds to the Office Action dated May 24, 2000 (Paper No. 12), sent in connection with the above-referenced application. This Amendment is being timely filed in view of the accompanying petition for a Three Month Extension of Time, and associated fee, which extends the time for a response to the Office Action to and through November 24, 2000.

## REMARKS

The present application is a continuation-in-part of PCT Application No. US/PCT9604407, filed on March 28, 1996, which is a continuation of U.S. Application No. 08/412,066, filed on March 28, 1995, all of which are entitled to priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/006,627, filed on November 13, 1995.

The present invention relates to novel isolated marrow stromal cells ("MSCs") for use in treatment of a central nervous system ("CNS") disease, disorder or condition. The invention discloses methods comprising administering isolated marrow stromal cells into the CNS of a human patient thereby effecting treatment of a disease, disorder or condition thereof. Moreover, the stromal cells may be cultured *in vitro*,